Harvard Health Letter

New pill better targets rheumatoid arthritis

In November 2012 the FDA approved a new treatment for people with rheumatoid arthritis called tofacitinib (Xeljanz). Unlike previous biologic treatments, the new drug is a pill, not an injection, and it targets another type of inflammatory molecule.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In